港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

医药外包概念

1,777.959

+5.7270.32%

涨家数：2

跌家数：5

平家数：1

市盈率：- -

高：1,779.268

开：1,770.415

低：1,747.549

收：1,772.232

数据加载中...

总览新闻资讯

华东医药(000963.SZ)：多肽类人GLP-1受体和GIP受体的双靶点长效激动剂HDM1005注射液临床试验获批

药明康德将于3月17日审议年度业绩及股息策略

康龙化成收盘上涨1.51%，滚动市盈率25.33倍，总市值477.27亿元

康龙化成3月3日现1笔大宗交易成交金额1333.5万元

新浪证券-红岸工作室

昭衍新药(06127)截至2月末累计回购A股股份326.98万股

智通财经网

【黑石拟收购日本临床研究机构CMIC六成权益或涉及数亿美元】全球最大另类资产管理人黑石正收购一家专注于帮助制药公司在日本进行临床试验的公司CMIC Co.，反映其对日本老龄化人口健康需求的兴趣日益增加。据悉，黑石同意收购CMIC Co. 60%股权，惟未有透露具体金额，仅指交易的价值可达数亿美元。黑石日本私募股权主管Atsuhiko Sakamoto曾在访问中表示，日本的临床试验过程效率颇低，对比其他市场需时非常长。它们目前将简化过程，可以更快介绍新药到日本，而黑石可以从中作出贡献。

港股异动 | 来凯医药-B(02105)涨超8% 自研新药LAE120获美国FDA临床试验批准

方达控股盘中异动股价大跌7.32%

药明康德盘中异动股价大涨3.03%

昭衍新药盘中异动股价大涨5.75%报13.980港元

药明生物(02269)出现大手卖出31.45万股，成交价$22.45，涉资706.052万

阿斯达克财经

【百利天恒：BL-B01D1（EGFR×HER3 双抗 ADC）联合奥希替尼用于一线 EGFR 突变型局部晚期或转移性非小细胞肺癌 III 期临床试验完成首例受试者入组】金融界3月2日消息，百利天恒自主研发的创新生物药注射用 BL-B01D1（EGFR×HER3 双抗 ADC）联合奥希替尼用于一线 EGFR 突变型局部晚期或转移性非小细胞肺癌的 III 期临床试验已于近日完成首例受试者入组。BL-B01D1 是全球独家处于 III 期注册临床试验阶段的可同时靶向 EGFR 和 HER3 的双抗 ADC 药物。截至目前，BL-B01D1 正在中国和美国进行约 30 项针对多种肿瘤类型的临床试验，除本次新入组的临床试验外，其在肺癌、乳腺癌、鼻咽癌、食管鳞癌等 7 项国内 III 期注册临床试验也处于受试者入组阶段。药品需完成临床试验并通过审评审批方可上市销售，且医药产品具有高科技、高风险等特点，容易受到不确定性因素影响。

康希诺业绩出炉，营收大增137%，股价不涨反跌？

昆药集团(600422.SH)：天麻素注射液临床试验获批准

泰格医药02月28日遭主力抛售483万元

昭衍新药02月28日遭主力抛售492万元

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/BK1576/news?page=6"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1576"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1576\",,,,,undefined,":{"symbol":"BK1576","market":"HK","secType":"PLATE","nameCN":"医药外包概念","latestPrice":1777.9586,"timestamp":1741312993544,"preClose":1772.232,"halted":0,"volume":13944558,"delay":0,"changeRate":0.003231,"change":5.726563,"pbRate":2.648404,"amount":328368897,"amplitude":0.017898,"prevYearClose":1395.7731,"fiveDayClose":1699.456,"twentyDayClose":1588.191,"turnoverRate":0.001229,"marketCap":381470258944,"floatMarketCap":165331562496,"peRate":33.012456},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1576\",,,,,undefined,":{"symbol":"BK1576","high":1779.2683,"amplitude":0.017898,"preClose":1772.232,"low":1747.5487,"pbRate":"2.648404","latestPrice":1777.9586,"volume":13944558,"delay":0,"open":1770.415,"prevYearClose":1395.7731,"prevWeekClose":1699.456,"prevMonthClose":1699.456,"prevQuarterClose":1395.773,"fiveDayClose":1699.456,"twentyDayClose":1588.191,"sixtyDayClose":1337.64,"secType":"PLATE","market":"HK","turnoverRate":0.001229,"peRate":33.012456,"marketCap":381470258944,"floatMarketCap":165331562496,"timestamp":1741312993544,"nameCN":"医药外包概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1576\",,,,undefined,":{"bkCode":"BK1576","up":2,"down":5,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1576\",pageSize:16,pageCount:6,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2516856686","title":"华东医药(000963.SZ)：多肽类人GLP-1受体和GIP受体的双靶点长效激动剂HDM1005注射液临床试验获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2516856686","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516856686?lang=zh_cn&edition=fundamental","pubTime":"2025-03-03 17:47","pubTimestamp":1740995243,"startTime":"0","endTime":"0","summary":"据悉，HDM1005注射液是由杭州中美华东制药有限公司研发并拥有全球知识产权的1类化学新药，是多肽类人GLP-1受体和GIP受体的双靶点长效激动剂。HDM1005注射液为多肽类人GLP-1受体和GIP受体的双靶点长效激动剂，GLP-1类产品具有减肥、降糖和心血管获益等作用，是相对成熟和安全的靶点。本次HDM1005注射液临床试验获批，是该款产品研发进程中的又一重要进展，将进一步提升公司在内分泌治疗领域的核心竞争力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1256977.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0132","LU1969619763.USD","03347","BK4590","BK0175","000963","BK0188","BK4144","BK1141","BK0209","BK0196","GLP","BK1576","BK0183","BK0187","LU2328871848.SGD","BK1583"],"gpt_icon":0},{"id":"2516685550","title":"药明康德将于3月17日审议年度业绩及股息策略","url":"https://stock-news.laohu8.com/highlight/detail?id=2516685550","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516685550?lang=zh_cn&edition=fundamental","pubTime":"2025-03-03 17:44","pubTimestamp":1740995064,"startTime":"0","endTime":"0","summary":"3月3日，药明康德（603259/02359）发布公告，将于2025年3月17日召开董事会会议，主要内容包括考虑和批准截至2024年12月31日的年度业绩及建议的末期股息（如有）。公告并未透露具体的财务数据或业绩变化，因此无法提供相关的数字信息。此次董事会会议的召开旨在审议公司整体的经营情况及未来的股东回报策略。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202503033334901567.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1141","LU0052750758.USD","LU0320764599.SGD","LU2045819591.USD","LU2242644610.SGD","02359","BK1576","LU1046422090.SGD","LU0708995583.HKD","BK1583","LU2125910500.SGD"],"gpt_icon":0},{"id":"2516836896","title":"康龙化成收盘上涨1.51%，滚动市盈率25.33倍，总市值477.27亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516836896","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516836896?lang=zh_cn&edition=fundamental","pubTime":"2025-03-03 17:27","pubTimestamp":1740994020,"startTime":"0","endTime":"0","summary":"3月3日，康龙化成今日收盘26.84元，上涨1.51%，滚动市盈率PE达到25.33倍，总市值477.27亿元。从行业市盈率排名来看，公司所处的医疗服务行业市盈率平均47.53倍，行业中值43.87倍，康龙化成排名第18位。消息面上，康龙化成10月30日接待中金证券等38家机构调研，上市公司接待人员包括首席财务官、董事会秘书李承宗。最新一期业绩显示，2024年三季报，公司实现营业收入88.17亿元，同比3.00%；净利润14.22亿元，同比24.82%，销售毛利率33.87%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/03/03172748487215.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1141","BK0216","300759","BK1576","03759"],"gpt_icon":0},{"id":"2516688502","title":"康龙化成3月3日现1笔大宗交易 成交金额1333.5万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516688502","media":"新浪证券-红岸工作室","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516688502?lang=zh_cn&edition=fundamental","pubTime":"2025-03-03 17:00","pubTimestamp":1740992400,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 　　3月3日，康龙化成收涨1.51%，收盘价为26.84元，发生1笔大宗交易，合计成交量50万股，成交金额1333.5万元。　　第1笔成交价格为26.67元，成交50.00万股，成交金额1,333.50万元，溢价率为-0.63%，买方营业部为机构专用，卖方营业部为中信证券华南股份有限公司广州万博证券营业部。　　进一步统计，近3个月内该股累计发生15笔大宗交易，合计成交金额为2.21亿元。该股近5个交易日累计下跌5.53%，主力资金合计净流出1.3亿元。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：小浪快报","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/ggzz/2025-03-03/doc-inenkmnh6633129.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1141","03759","BK1576","300759","BK0216"],"gpt_icon":0},{"id":"2516683654","title":"昭衍新药(06127)截至2月末累计回购A股股份326.98万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2516683654","media":"智通财经网","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516683654?lang=zh_cn&edition=fundamental","pubTime":"2025-03-03 16:57","pubTimestamp":1740992257,"startTime":"0","endTime":"0","summary":"昭衍新药(06127)发布公告，2025年2月，公司未回购A股股份。截至2025年...","market":"sg","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_37.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_37.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1256925.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["159982","BK1141","603127","BK0216","BK1576","399300","06127"],"gpt_icon":0},{"id":"2516157074","title":"【黑石拟收购日本临床研究机构CMIC六成权益 或涉及数亿美元】全球最大另类资产管理人黑石正收购一家专注于帮助制药公司在日本进行临床试验的公司CMIC Co.，反映其对日本老龄化人口健康需求的兴趣日益增加。据悉，黑石同意收购CMIC Co. 60%股权，惟未有透露具体金额，仅指交易的价值可达数亿美元。黑石日本私募股权主管Atsuhiko Sakamoto曾在访问中表示，日本的临床试验过程效率颇低，对比其他市场需时非常长。它们目前将简化过程，可以更快介绍新药到日本，而黑石可以从中作出贡献。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516157074","media":"金融界","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516157074?lang=zh_cn&edition=fundamental","pubTime":"2025-03-03 14:39","pubTimestamp":1740983998,"startTime":"0","endTime":"0","summary":"全球最大另类资产管理人黑石正收购一家专注于帮助制药公司在日本进行临床试验的公司CMIC Co.，反映其对日本老龄化人口健康需求的兴趣日益增加。据悉，黑石同意收购CMIC Co. 60%股权，惟未有透露具体金额，仅指交易的价值可达数亿美元。黑石日本私募股权主管Atsuhiko Sakamoto曾在访问中表示，日本的临床试验过程效率颇低，对比其他市场需时非常长。它们目前将简化过程，可以更快介绍新药到日本，而黑石可以从中作出贡献。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/03143948480931.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["01477","BK4135","BX","BK4585","BK1583","IE00BGHQF748.EUR","BK1576","09983","BK1191","IE00B3QW5Z07.USD","IE00BBT3K403.USD","BK1542","BK4588","BK1574","IE00BLSP4452.SGD","BK1141","IE00B64PRP62.GBP","BK1258","IE0004445239.USD","IE00BLSP4239.USD","IE00BN8TJ469.HKD","03347","BK1229"],"gpt_icon":0},{"id":"2516575333","title":"港股异动 | 来凯医药-B(02105)涨超8% 自研新药LAE120获美国FDA临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2516575333","media":"智通财经","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516575333?lang=zh_cn&edition=fundamental","pubTime":"2025-03-03 11:29","pubTimestamp":1740972568,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，来凯医药-B涨超8%，截至发稿，涨8.63%，报13.6港元，成交额8370.23万港元。消息面上，来凯医药今早宣布，美国食品药品监督管理局已批准其自主研发的LAE120，一种强效、高选择性USP1抑制剂的新药临床试验申请，用于治疗晚期实体瘤患者。公司表示正积极开展外部合作以加快LAE120临床开发进展。除LAE120，来凯自主研发的另一款抗肿瘤潜在药物LAE118也进入了IND支持性研究阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1256765.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02105","BK1161","03347","BK1576","BK1141","BK1583"],"gpt_icon":0},{"id":"2516827578","title":"方达控股盘中异动 股价大跌7.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516827578","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516827578?lang=zh_cn&edition=fundamental","pubTime":"2025-03-03 10:43","pubTimestamp":1740969816,"startTime":"0","endTime":"0","summary":"2025年03月03日早盘10时43分，方达控股股票出现波动，股价急速下跌7.32%。截至发稿，该股报1.140港元/股，成交量62.6万股，换手率0.03%，振幅8.13%。资金方面，该股资金流入12.184万港元，流出58.574万港元。机构评级方面，在所有1家参与评级的机构中，100%的券商给予卖出建议，无券商给予买入、持有建议。方达控股股票所在的生物技术行业中，整体涨幅为0.14%。北美和欧洲部门包括美国、加拿大和欧洲。中国部门包括中国。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303104336989943e1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303104336989943e1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","BK1576","BK1583","01521"],"gpt_icon":0},{"id":"2516752201","title":"药明康德盘中异动 股价大涨3.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516752201","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516752201?lang=zh_cn&edition=fundamental","pubTime":"2025-03-03 09:52","pubTimestamp":1740966740,"startTime":"0","endTime":"0","summary":"2025年03月03日早盘09时52分，药明康德股票出现异动，股价快速拉升3.03%。截至发稿，该股报61.150港元/股，成交量103.643万股，换手率0.27%，振幅2.95%。资金方面，该股资金流入3389.47万港元，流出1549.52万港元。药明康德股票所在的生物技术行业中，整体跌幅为1.33%。其相关个股中，昭衍新药、科济药业-B、云顶新耀-B涨幅较大，振幅较大的相关个股有创胜集团-B、永泰生物-B、百奥赛图-B，振幅分别为20.41%、11.31%、10.55%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025030309522098993174&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025030309522098993174&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2125910500.SGD","LU1046422090.SGD","LU0320764599.SGD","LU0708995583.HKD","BK1576","BK1583","LU0052750758.USD","BK1141","02359","LU2045819591.USD","LU2242644610.SGD"],"gpt_icon":0},{"id":"2516524796","title":"昭衍新药盘中异动 股价大涨5.75%报13.980港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516524796","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516524796?lang=zh_cn&edition=fundamental","pubTime":"2025-03-03 09:44","pubTimestamp":1740966258,"startTime":"0","endTime":"0","summary":"2025年03月03日早盘09时44分，昭衍新药股票出现波动，股价急速上涨5.75%。截至发稿，该股报13.980港元/股，成交量60.84万股，换手率0.51%，振幅4.99%。资金方面，该股资金流入457.631万港元，流出235.721万港元。昭衍新药股票所在的生物技术行业中，整体涨幅为0.23%。其相关个股中，昭衍新药、科济药业-B、圣诺医药-B涨幅较大，振幅较大的相关个股有创胜集团-B、永泰生物-B、腾盛博药-B，振幅分别为20.41%、11.31%、8.85%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303094418abe537b5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303094418abe537b5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06127","BK1141","BK1576"],"gpt_icon":0},{"id":"2516727521","title":"药明生物(02269)出现大手卖出31.45万股，成交价$22.45，涉资706.052万","url":"https://stock-news.laohu8.com/highlight/detail?id=2516727521","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516727521?lang=zh_cn&edition=fundamental","pubTime":"2025-03-03 09:20","pubTimestamp":1740964800,"startTime":"0","endTime":"0","summary":"[大手成交]药明生物(02269)在上午09:20出现大手卖出，成交量为31.45万，成交价为港币$22.45，涉资706.052万。至目前为止，股价无升跌，今日最高价为$22.45，而最低价为$22.45，总成交量为198.385万股，总成交金额港币$4.449千万。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205145550051_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205145550051_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT25030358/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU0572944931.SGD","LU0823426308.USD","02269","LU0516422952.EUR","LU0516422366.SGD","LU0326950275.SGD","LU0359202008.SGD","LU1688375341.USD","LU0516422440.USD","LU0327786744.USD","BK1141","LU0140636845.USD","LU0348735423.USD","LU0181495838.USD","LU0588546209.SGD","LU0979878070.USD","LU1242518857.USD","LU0823426480.USD","LU1720050803.USD","SG9999002463.SGD","LU0456846285.SGD","LU0456827905.SGD","LU0052750758.USD","LU0516423174.USD","LU1242518931.SGD","LU0819121731.USD","LU1794554557.SGD","IE00B0JY6N72.USD","LU0039217434.USD","BK1589","LU0856984785.SGD","LU0708995583.HKD","LU0516423091.SGD","SG9999002562.SGD","LU2039709279.SGD","LU0307460666.USD","BK1521","BK1610","LU0320764599.SGD","LU0417516738.SGD","LU0417516902.SGD","LU0043850808.USD","BK1576","LU0359201612.USD","LU0051755006.USD","LU0348825331.USD","LU1880383366.USD"],"gpt_icon":0},{"id":"2516364590","title":"【百利天恒：BL-B01D1（EGFR×HER3 双抗 ADC）联合奥希替尼用于一线 EGFR 突变型局部晚期或转移性非小细胞肺癌 III 期临床试验完成首例受试者入组】金融界3月2日消息，百利天恒自主研发的创新生物药注射用 BL-B01D1（EGFR×HER3 双抗 ADC）联合奥希替尼用于一线 EGFR 突变型局部晚期或转移性非小细胞肺癌的 III 期临床试验已于近日完成首例受试者入组。BL-B01D1 是全球独家处于 III 期注册临床试验阶段的可同时靶向 EGFR 和 HER3 的双抗 ADC 药物。截至目前，BL-B01D1 正在中国和美国进行约 30 项针对多种肿瘤类型的临床试验，除本次新入组的临床试验外，其在肺癌、乳腺癌、鼻咽癌、食管鳞癌等 7 项国内 III 期注册临床试验也处于受试者入组阶段。药品需完成临床试验并通过审评审批方可上市销售，且医药产品具有高科技、高风险等特点，容易受到不确定性因素影响。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516364590","media":"金融界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516364590?lang=zh_cn&edition=fundamental","pubTime":"2025-03-02 15:34","pubTimestamp":1740900843,"startTime":"0","endTime":"0","summary":"金融界3月2日消息，百利天恒自主研发的创新生物药注射用 BL-B01D1 联合奥希替尼用于一线 EGFR 突变型局部晚期或转移性非小细胞肺癌的 III 期临床试验已于近日完成首例受试者入组。BL-B01D1 是全球独家处于 III 期注册临床试验阶段的可同时靶向 EGFR 和 HER3 的双抗 ADC 药物。截至目前，BL-B01D1 正在中国和美国进行约 30 项针对多种肿瘤类型的临床试验，除本次新入组的临床试验外，其在肺癌、乳腺癌、鼻咽癌、食管鳞癌等 7 项国内 III 期注册临床试验也处于受试者入组阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/02153448475153.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0239","09939","159839","BK1576","BK4231","ADC","BK1574","III","688506","LU1815336091.USD","BK1161","03347","BK1515","BK4134","BK1141","BK4023","BK4080","159938","BL","LU0757428866.USD","BK1583"],"gpt_icon":0},{"id":"2516372983","title":"康希诺业绩出炉，营收大增137%，股价不涨反跌？","url":"https://stock-news.laohu8.com/highlight/detail?id=2516372983","media":"财华社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516372983?lang=zh_cn&edition=fundamental","pubTime":"2025-02-28 19:26","pubTimestamp":1740741978,"startTime":"0","endTime":"0","summary":"昨日，港股的疫苗企业康希诺生物（06185.HK）发布2024年度业绩快报，表现可圈可点。根据其A股三季报，康希","market":"us","thumbnail":"https://images.finet.hk/photoLib/title/202502_1/05a175fc-813c-4bc3-95e8-bed2a53c298e.png","type":0,"news_type":0,"thumbnails":["https://images.finet.hk/photoLib/title/202502_1/05a175fc-813c-4bc3-95e8-bed2a53c298e.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.finet.hk/newscenter/news_content/67c19d5a23082975a38f607b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"finet_stock","symbols":["LU1242518931.SGD","LU0359202008.SGD","SG9999002463.SGD","06185","LU0516422440.USD","LU1880383366.USD","LU0979878070.USD","LU0516422952.EUR","LU0140636845.USD","LU1242518857.USD","LU0417516738.SGD","LU0456827905.SGD","BK1161","LU0516422366.SGD","LU0708995583.HKD","LU0326950275.SGD","LU0819121731.USD","LU1794554557.SGD","LU0320764599.SGD","LU0456846285.SGD","LU0823426480.USD","BK1610","LU0052750758.USD","BK1521","LU0516423174.USD","LU0823426308.USD","BK1583","LU0327786744.USD","LU0043850808.USD","LU0181495838.USD","LU0051755006.USD","LU0856984785.SGD","BK1141","01877","SG9999002562.SGD","LU0572944931.SGD","LU0588546209.SGD","LU0348735423.USD","BK1589","BK1515","LU2039709279.SGD","LU0359201612.USD","BK1191","BK1576","LU0307460666.USD","BK1574","LU0516423091.SGD","LU1688375341.USD","LU0348825331.USD"],"gpt_icon":1},{"id":"2514435243","title":"昆药集团(600422.SH)：天麻素注射液临床试验获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2514435243","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514435243?lang=zh_cn&edition=fundamental","pubTime":"2025-02-28 17:15","pubTimestamp":1740734140,"startTime":"0","endTime":"0","summary":"智通财经APP讯，昆药集团(600422.SH)公告，公司近日收到国家药品监督管理局签发的天麻素注射液按照化学药品2.4类新药受理的《药物临床试验批准通知书》，同意该新药开展相关临床试验研究，该新药适应症为：预防心脏外科术后谵妄。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1256185.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","600422","03347","BK1576","BK0239","BK0060","BK1583","BK0188","BK0028"],"gpt_icon":0},{"id":"2514348825","title":"泰格医药02月28日遭主力抛售483万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514348825","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514348825?lang=zh_cn&edition=fundamental","pubTime":"2025-02-28 16:17","pubTimestamp":1740730640,"startTime":"0","endTime":"0","summary":"02月28日, 泰格医药股价跌6.88%，报收33.85元，成交金额1.78亿元，换手率4.16%，振幅9.90%，量比0.71。泰格医药今日主力资金净流出483万元，上一交易日主力净流出37万元。该股近5个交易日下跌13.08%，主力资金累计净流出2704万元；近20日主力资金累计净流入1251万元，其中净流入天数为8日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228165711a2579d8d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228165711a2579d8d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03347","BK1141","BK1576","BK1583"],"gpt_icon":0},{"id":"2514348385","title":"昭衍新药02月28日遭主力抛售492万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514348385","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514348385?lang=zh_cn&edition=fundamental","pubTime":"2025-02-28 16:16","pubTimestamp":1740730597,"startTime":"0","endTime":"0","summary":"02月28日, 昭衍新药股价跌15.04%，报收13.22元，成交金额8936万元，换手率5.41%，振幅17.74%，量比0.86。昭衍新药今日主力资金净流出492万元，上一交易日主力净流出145万元。该股近5个交易日下跌2.81%，主力资金累计净流出88万元，其中2个交易日为股价上涨时净流出；近20日主力资金累计净流入2110万元，其中净流入天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228165606a2579d0f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228165606a2579d0f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1576","06127","BK1141"],"gpt_icon":0}],"pageSize":16,"totalPage":14,"pageCount":6,"totalSize":220}]}}